Total Payments
$292,376
2024 Payments
$78,397
Companies
41
Transactions
411
Medicare Patients
1,057
Medicare Billing
$116,785
Payment Breakdown by Category
Other$176,891 (60.5%)
Consulting$53,201 (18.2%)
Travel$51,492 (17.6%)
Food & Beverage$9,612 (3.3%)
Research$1,181 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $127,453 | 49 | 43.6% |
| Consulting Fee | $53,201 | 27 | 18.2% |
| Travel and Lodging | $51,492 | 124 | 17.6% |
| Honoraria | $49,410 | 24 | 16.9% |
| Food and Beverage | $9,612 | 182 | 3.3% |
| Unspecified | $1,181 | 4 | 0.4% |
| Grant | $28.57 | 1 | 0.0% |
Payments by Type
General
$291,195
407 transactions
Research
$1,181
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $147,763 | 167 | $0 (2024) |
| UCB, Inc. | $37,010 | 54 | $0 (2024) |
| ARGENX US, INC. | $25,637 | 35 | $0 (2024) |
| Strongbridge US INC. | $23,581 | 35 | $0 (2018) |
| CSL Behring | $18,884 | 31 | $0 (2024) |
| Amgen Inc. | $14,725 | 9 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $9,628 | 11 | $0 (2024) |
| CATALYST PHARMACEUTICALS, INC. | $4,444 | 5 | $0 (2024) |
| Biogen, Inc. | $2,841 | 3 | $0 (2023) |
| Alnylam Pharmaceuticals Inc. | $2,700 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $78,397 | 127 | ARGENX US, INC. ($22,721) |
| 2023 | $32,467 | 61 | UCB, Inc. ($15,886) |
| 2022 | $60,723 | 64 | Alexion Pharmaceuticals, Inc. ($59,231) |
| 2021 | $15,316 | 12 | Alexion Pharmaceuticals, Inc. ($7,621) |
| 2020 | $20,282 | 27 | CSL Behring ($11,957) |
| 2019 | $21,381 | 38 | Alexion Pharmaceuticals, Inc. ($12,886) |
| 2018 | $58,556 | 71 | Alexion Pharmaceuticals, Inc. ($34,667) |
| 2017 | $5,254 | 11 | Alexion Pharmaceuticals, Inc. ($5,235) |
All Payment Transactions
411 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Neurology | ||||||
| 12/12/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $876.96 | General |
| Category: Neurology | ||||||
| 12/12/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $428.18 | General |
| Category: Neurology | ||||||
| 12/12/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $428.18 | General |
| Category: Neurology | ||||||
| 12/12/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $80.00 | General |
| Category: Neurology | ||||||
| 12/12/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $77.33 | General |
| Category: Neurology | ||||||
| 12/12/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $25.43 | General |
| Category: Neurology | ||||||
| 12/03/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Neurology | ||||||
| 12/03/2024 | Grifols USA, LLC | Gamunex-C (Biological) | Food and Beverage | In-kind items and services | $28.49 | General |
| Category: Immunology and Neurology | ||||||
| 12/02/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: Rare Disease | ||||||
| 11/20/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: Neurology | ||||||
| 11/12/2024 | UCB, Inc. | Rystiggo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,080.00 | General |
| Category: Neurology | ||||||
| 11/11/2024 | Alexion Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,470.00 | General |
| 11/11/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| 11/11/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $12.31 | General |
| Category: Neurology | ||||||
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,470.00 | General |
| Category: Rare Disease | ||||||
| 10/28/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/24/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $124.74 | General |
| Category: Neurology | ||||||
| 10/23/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $391.28 | General |
| Category: Neurology | ||||||
| 10/23/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $317.92 | General |
| Category: Neurology | ||||||
| 10/23/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: Neurology | ||||||
| 10/18/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $27.53 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 10/15/2024 | Amgen Inc. | UPLIZNA (Biological) | Consulting Fee | Cash or cash equivalent | $5,517.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/15/2024 | Amgen Inc. | UPLIZNA (Biological) | Consulting Fee | Cash or cash equivalent | $1,839.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/15/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $134.05 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | Alexion Pharmaceuticals, Inc. | $1,181 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 201 | 233 | $49,769 | $21,276 |
| 2022 | 9 | 210 | 246 | $52,837 | $23,976 |
| 2021 | 9 | 265 | 317 | $72,410 | $29,868 |
| 2020 | 11 | 381 | 447 | $99,270 | $41,664 |
Total Patients
1,057
Total Services
1,243
Medicare Billing
$116,785
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 56 | 57 | $18,195 | $6,613 | 36.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 43 | 54 | $9,180 | $4,746 | 51.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 28 | $6,608 | $3,217 | 48.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 23 | $4,002 | $2,000 | 50.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 18 | 24 | $4,488 | $1,787 | 39.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 25 | 29 | $3,678 | $1,724 | 46.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 15 | 18 | $3,618 | $1,189 | 32.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 40 | 42 | $13,818 | $6,121 | 44.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 44 | 54 | $9,180 | $4,846 | 52.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 34 | $8,024 | $4,531 | 56.5% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 25 | 32 | $6,432 | $2,454 | 38.2% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 14 | 15 | $5,910 | $1,935 | 32.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $3,822 | $1,465 | 38.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 16 | $1,824 | $1,115 | 61.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 13 | 20 | $2,440 | $935.33 | 38.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 15 | 19 | $1,387 | $572.95 | 41.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 67 | 67 | $22,043 | $9,814 | 44.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 52 | 69 | $11,730 | $5,458 | 46.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 36 | 47 | $11,092 | $4,629 | 41.7% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 30 | 42 | $8,344 | $3,102 | 37.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 21 | 21 | $5,733 | $2,523 | 44.0% |
| 95910 | Nerve transmission studies, 7-8 studies | Office | 2021 | 12 | 12 | $4,728 | $1,328 | 28.1% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 25 | 37 | $2,701 | $1,106 | 40.9% |
| 95909 | Nerve transmission studies, 5-6 studies | Office | 2021 | 11 | 11 | $3,289 | $969.53 | 29.5% |
| 95908 | Nerve transmission studies, 3-4 studies | Office | 2021 | 11 | 11 | $2,750 | $939.40 | 34.2% |
About Amit Sachdev, M.D., MS
Amit Sachdev, M.D., MS is a Neurology healthcare provider based in East Lansing, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2010. The National Provider Identifier (NPI) number assigned to this provider is 1962720797.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Amit Sachdev, M.D., MS has received a total of $292,376 in payments from pharmaceutical and medical device companies, with $78,397 received in 2024. These payments were reported across 411 transactions from 41 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($127,453).
As a Medicare-enrolled provider, Sachdev has provided services to 1,057 Medicare beneficiaries, totaling 1,243 services with total Medicare billing of $116,785. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location East Lansing, MI
- Active Since 05/04/2010
- Last Updated 06/27/2023
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1962720797
Products in Payments
- ULTOMIRIS (Biological) $53,245
- SOLIRIS (Drug) $41,575
- KEVEYIS (Drug) $23,581
- Rystiggo (Drug) $18,758
- Hizentra (Biological) $17,324
- UPLIZNA (Biological) $14,725
- Zilbrysq (Drug) $14,145
- VYVGART HYTRULO (Drug) $13,200
- VYVGART (Drug) $11,008
- FIRDAPSE (Drug) $4,422
- Soliris (Drug) $3,990
- SOLIRIS (Biological) $3,827
- ONPATTRO (Drug) $2,700
- Rystiggo (Biological) $2,548
- TEGSEDI (Drug) $2,440
- Privigen (Biological) $1,560
- ULTOMIRIS (Drug) $1,181
- GENERAL THERAPIES (Device) $307.94
- Briviact (Drug) $114.87
- NURTEC ODT (Drug) $108.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in East Lansing
Dr. Mounzer Yassin-Kassab, M.d, M.D
Neurology — Payments: $386,102
Neurology $386,102
Dr. Jayne Ward, D.o, D.O
Neurology — Payments: $366,840
Neurology $366,840
Dr. Tariq Gheith, M.d, M.D
Neurology — Payments: $218,666
Neurology $218,666
Dr. Larry Charleston, M.d, M.D
Neurology — Payments: $211,437
Neurology $211,437
Dr. Anmar Razak, M.d, M.D
Neurology — Payments: $146,635
Neurology $146,635
Dr. John Goudreau, D.o, D.O
Neurology — Payments: $95,463
Neurology $95,463